Daihong Liu

This study is for people with a hard-to-treat type of aggressive B-cell lymphoma that has come back or hasn't responded to other treatments. Researchers want to see if giving two additional drugs (chidamide and a PD-1 inhibitor) as maintenance therapy after a person's own immune …

This study is testing a new type of CAR-T cell therapy for people with multiple myeloma who also have kidney problems. The therapy uses the patient's own modified immune cells to target the cancer. Researchers want to see if this treatment can help control the myeloma and improve…

This early-stage study is testing a new cell therapy for patients who develop a dangerous Epstein-Barr virus (EBV) infection after a stem cell transplant. The main goal is to find a safe dose of specially prepared immune cells designed to fight the virus. Researchers will also ch…

This study tests a new cell therapy for patients who develop Epstein-Barr virus infections after receiving a stem cell transplant. Researchers are using genetically engineered immune cells designed to specifically target and eliminate virus-infected cells. The trial will evaluate…

This study is testing a new type of CAR-T cell therapy for people with B-cell lymphoma or leukemia that has come back or hasn't responded to standard treatments. Instead of modifying a patient's T cells in a lab, the therapy uses tiny particles to deliver genetic instructions dir…

This early-stage study is testing a new cell therapy called EBV-AST for adults with lymphomas linked to the Epstein-Barr virus (EBV). The main goals are to check if the treatment is safe and to find the best dose. Researchers will give participants up to three infusions of specia…

This study is testing if adding a drug called ruxolitinib to the standard steroid treatment works better for controlling a serious immune reaction called acute GVHD. It is for adults who have had a stem cell transplant for blood cancer and develop this complication. The goal is t…